5 Adenocarcinoma 7 17 Papillary serous 6 15 Clear cell adenocarcinoma 2 5 Endometrioid 3 7 Mucinous adenocarcinoma 3 7 Poorly differentiated 10 24.5 Stage at diagnosis     I,II 2 5 III (A, B, C) 33 (10, 12, 11) 80 IV 6 15 N of prior chemotherapy regimens     1 3 7 2 12 29 ≥3 26 64 N of prior Akt inhibitor platinum-based regimens     1 23 56 2 9 22 3 9 22 Abbreviations: ECOG PS, Eastern Cooperative Oncoloy Group Performance Status. Efficacy A median number of 8 cycles of GEMOX were administered (range, 2 to 12). One patient refused further treatment after the 2nd chemotherapy cycle. All patients were fully evaluable for RNA Synthesis inhibitor response and toxicity. Based on ITT analysis, 2 (5%) complete responses (CR) and 13 (32%)

partial responses (PR) were observed in 41 enrolled patients, for an overall response rate of 37% (95% CI, 22.3 to-51.7%.). Stable disease was observed in 17 patients (41%). A clinical benefit (objective responses + stable disease) was documented

in 32 patients (78%) (95% CI, 65–91) (Table 2). Among patients whose disease was originally partially platinum-sensitive, response rate BIIB057 order was 50%, while in platinum-resistant or refractory patients response rate was 26%. The PFS was 6.8 months (95% CI, 5.8–7.8) (Figure 1), with no significant difference between initially platinum-sensitive and platinum-resistant patients (7.0 and 6.7 months, respectively). After a median follow-up of 14.5 months (range, 2 to 30), 69.2% and 10.1% patients were alive at 1 and 2 years, respectively; the median OS for the whole cohort was 16.5 months (95% CI, 12.2–20.8) (Figure 2). The median time to self-reported symptom relief, which occurred in 22 out of 27 symptomatic patients (81.5%), Adenosine was 4 weeks (range, 2–8 weeks); even if symptom improvement translated into objective response in only 8 patients, some degree of amelioration in quality of life was reported by the vast majority of symptomatic patients. Figure 1 Progression free survival (PFS). Table 2 Objective response

in 41 patients Responses No. of patients % Complete response 2 5 Partial response 13 32 Stable disease 17 41 Progressive disease 9 22 Clinical Benefit 32 78 Figure 2 Overall survival (OS). Toxicity The dose-limiting toxicity was hematological, with G4 neutropenia and febrile neutropenia observed in 2 (5%) patients and 1 (2.5%) patient, respectively, requiring G-CSF administration. G1-2 thrombocytopenia were observed in 4 (10%) and 6 (15%) patients, respectively; no cases of G3 or G4 thrombocytopenia were reported. Grade 3 anemia was encountered in 2 (5%) patients, whereas G1-2 anemia was commonly observed (34% and 29%, respectively). Treatment delays because of hematological or extra-hematological toxicities were needed in 4 patients (9.7%). Dose-reductions were required in 3 (7.3%) patients because of G2 neurotoxicity. No cases of G3 or more severe neurotoxicity were observed, while G1 neurotoxicity occurred in 2 patients (5%).